A Screening Test for HLA-B∗15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events

• Hoofdauteurs: Hua Fang (Auteur), Xiequn Xu (Auteur), Kulvinder Kaur (Auteur), Matthew Dedek (Auteur), Guang-dan Zhu (Auteur), Bae J. Riley (Auteur), Frank G. Espin (Auteur), Andria L. Del Tredici (Auteur), Tanya A. Moreno (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2019-03-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Purpose:HLA-B∗15:02 is strongly associated with life-threatening severe skin hypersensitivity reactions in patients treated with carbamazepine (CBZ) and structurally related medications. FDA-approved labeling recommends HLA-B∗15:02 screening before CBZ therapy in patients of Asian ancestry. In this...